Scarica il programma in formato PDF

(1)

Mind, Feelings and the Best of NSCLC Therapy

Wednesday, March 28

^th

, 2018 Ospedale San Raffaele IRCCS

Scientific Committee

Luca Gianni Vanesa Gregorc

Provider CME, Scientific and Organizational Secretariat

CME ID 2157-217898

The Congress “Mind, Feelings, and the Best of NSCLC Therapy”, have been awarded 8 Credits for the following professions: medical surgeon (all disciplines), biologist, nurse, hospital phar- macist, health care assistant. The event is creditated to a maximum of 100 partecipants. The credits will be provided with a complete participation in scientific work and learning exam with at least 75% of correct answers.

Inscription:

Membership is free and entitles you to participation in Congress, Conference kit, certificate of attendance, coffee-break and lunch buffet. To enroll, send your personal data (name, surna- me, telephone number, e-mail), to the following address email: info@medicacom.it, or at the following fax number: 02 93661995. For organizational purposes, entries must be received by March 27^th, 2018.

PATRONAGE ON REQUEST

AIOM/CIPOMO/ROL/SIAPEC - IAP WITH THE UNRESTRICTED GRANT OF

CONGRESS VENUE

Congress Center San Raffaele – Dibit 1 – Via Olgettina, 58 – 20132 Milano How to reach congress venue

• MM2 Green line, stop Cascina Gobba + 923 Bus with stop in front of Dibit 1

• Tangenziale Est: from North exit Cascina Gobba / from South exit Segrate

PROVIDER CME, SCIENTIFIC AND ORGANIZATIONAL SECRETARIAT Medica Editoria e Diffusione Scientifica

Corso Buenos Aires 43 – 20124 Milano Tel +39 02 7628 1337

Fax +39 02 9366 1995

info@medicacom.it / www.medicacom.it SCIENTIFIC COMMITTEE

Luca Gianni: Dipartimento di Oncologia Medica – Ospedale San Raffaele Istituto di Ricovero e Cura a Carattere Scientifico, Milano

Vanesa Gregorc: Coordinatore area Oncologia Toracica e Melanoma, Dipartimento di Oncologia Medica – Ospedale San Raffaele Istituto di Ricovero e Cura a Carattere Scientifico, Milano FACULTY

Giampaolo Bianchini: Dirigente Medico Oncologia Medica, Day Hospital,

Macroattività ambulatoriale complessa - Ospedale San Raffaele Istituto di Ricovero e Cura a Carattere Scientifico, Milano

Alessandra Bulotta: Dipartimento di Oncologia Medica – Ospedale San Raffaele Istituto di Ricovero e Cura a Carattere Scientifico, Milano

Federico Cappuzzo: Direttore Unità Operativa di Oncologia di Ravenna, Lugo e Faenza – Direttore Dipartimento di Oncoematologia di Ravenna

Francesca Colonese: UO Oncologia – Azienda Ospedaliera San Gerardo, Monza

Diego Cortinovis: Unità Complessa, Divisione di Oncologia Medica – Azienda Ospedaliera San Gerardo, Monza

Sebastien Couraud: Medical Oncology, Centre Hospitalier Universitaire de Lyon

Marina Garassino: Responsabile SS Oncologia Medica toraco-polmonare – Istituto Nazionale dei Tumori, Milano

Lorenza Landi: UO di Oncologia di Ravenna, Lugo e Faenza

Chiara Lazzari: Dipartimento di Oncologia Medica – Ospedale San Raffaele stituto di Ricovero e Cura a Carattere Scientifico, Milano

Niki Karachaliou: Translational Research Group in Pangaea Biotech SA, Barcelona

Umberto Malapelle: Anatomia Patologica, Dipartimento di Sanità Pubblica – Università degli Studi di Napoli Federico II

Maria Rita Migliorino: Responsabile UOSD di Pneumologia Oncologica – Azienda ospedaliera San Camillo Forlanini, Roma

Alessandro Morabito: Direttore di Struttura Complessa di Oncologia Medica

Toraco-Polmonare, Divisione di Oncologia Medica, Dipartimento Toraco-Polmonare – Istituto Nazionale Tumori Fondazione Pascale, Napoli

Silvia Novello: Professore Ordinario di Oncologia Medica presso il Dipartimento di Oncologia Università di Torino

Elisa Roca: Oncologia Medica – Spedali Civili di Brescia

Christian Rolfo: Clinical Trial Management Program Oncology Department University Hospital Antwerp UZA, Belgium

Antonio Rossi: Dirigente Medico Divisione di Oncologia Medica IRCCS – “Casa Sollievo della Sofferenza”, San Giovanni Rotondo (FG)

Marcello Tiseo: Dirigente Medico, Oncologia Medica – AOU, Parma

Luca Toschi: UO Oncologia ed Ematolgia – Istituto Clinico Humanitas – IRCCS, Milano

(2)

SCIENTIFIC PROGRAM

09.00 - 09.30 Welcome and Registration 09.30 - 09.45 Introduction and meeting aims

Luca Gianni, Vanesa Gregorc

SESSION MULTIDISCIPLINARITY

Chairmen: Vanesa Gregorc, Antonio Rossi 09.45 - 10.15 Lecture

Multidisciplinarity and national networking for NSCLC diagnostics Sebastien Couraud

10.15 - 10.30 Case History

Multidisciplinarity matters Chiara Lazzari

10.30 - 11.15 Focus on discussion

Ask: Lorenza Landi, Luca Toschi

Reply: Sebastien Couraud, Chiara Lazzari, Umberto Malapelle

SESSION EGFRm NSCLC

Chairmen: Rita Migliorino, Alessandro Morabito 11.15 - 11.45 Lecture

Current and emerging approaches in the treatment of EGFRm NSCLC patients

Niki Karachaliou 11.45 - 12.00 Case History

Sequential therapy: open questions Alessandra Bulotta

Ask: Lorenza Landi, Antonio Rossi

Reply: Alessandra Bulotta, Niki Karachaliou, Umberto Malapelle 13.00 – 14.00 Lunch

SESSION ROS1 AND ALK REARRANGED NSCLC

Chairmen: Diego Cortinovis, Marcello Tiseo

14.00 - 14.20 Current and emerging approaches in the treatmnent of EML4-ALK positive NSCLC

Marina Garassino

14.20 - 14.40 Current and emerging treatment approaches to treat ROS-1 positive NSCLC

Federico Cappuzzo 14.40 - 14.55 Case History

Sequential therapy: open questions Elisa Roca

Ask: Alessandro Morabito, Rita Migliorino

Reply: Marina Garassino, Federico Cappuzzo, Elisa Roca

SESSION IMMUNOTHERAPY AND ANGIOGENESIS

Chairmen: Vanesa Gregorc, Silvia Novello

15.40 - 16.00 Immunotherapy in the first line setting Marcello Tiseo

16.00 - 16.20 Immunotherapy in the second line setting Diego Cortinovis

16.20 - 16.50 Lecture

Simple the best of immunotherapy: the future Christian Rolfo

16.50 - 17.10 Long Live the King Angiogenesis Antonio Rossi

17.10 - 17.25 Case History

Immunotherapy and angiogenesis Francesca Colonese

Ask: Giampaolo Bianchini, Luca Toschi

Reply: Diego Cortinovis, Francesca Colonese, Christian Rolfo, Marcello Tiseo 18.10 - 18.20 Closing Remarks

Vanesa Gregorc 18.20 - 18.30 ECM Questionnaires

BACKGROUND

Lung cancer remains the leading cause of cancer death worldwide, with an estimated five years overall survival of only 16%. Thanks to the technological advances, during the last ten years, different molecular alterations, responsible for the development of oncogene addicted tumors, have been identified in NSCLC.

Currently, NSCLC is not considered a single entity, but as a heterogeneous disease, including molecularly defined subsets of lung tumors.

One essential point in providing optimal care to lung cancer patients is the possibility to discuss and share the diagnostic and therapeutic program in a multidisciplinary team.